adenine has been researched along with Acute Lymphoid Leukemia in 10 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "After Phase I studies of benzisoquinolinedione (amonafide) in solid tumors identified myelosuppression as the dose-limiting toxicity, we conducted a Phase I study in patients with relapsed or refractory acute leukemia to define the optimal dose." | 9.07 | Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia. ( Benvenuto, JA; Beran, M; Estey, E; Felder, TB; Keating, M; O'Brien, S, 1991) |
| "After Phase I studies of benzisoquinolinedione (amonafide) in solid tumors identified myelosuppression as the dose-limiting toxicity, we conducted a Phase I study in patients with relapsed or refractory acute leukemia to define the optimal dose." | 5.07 | Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia. ( Benvenuto, JA; Beran, M; Estey, E; Felder, TB; Keating, M; O'Brien, S, 1991) |
| "Acute lymphoblastic leukemia (ALL) typically originates from pre-B cells that critically depend on survival signals emanating from a functional pre-BCR." | 2.52 | Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia. ( Müschen, M, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Godwin, CD | 1 |
| Bates, OM | 1 |
| Garling, EE | 1 |
| Beddoe, ME | 1 |
| Laszlo, GS | 1 |
| Walter, RB | 1 |
| Carlos, JAEG | 1 |
| Lima, K | 1 |
| Costa-Lotufo, LV | 1 |
| Leitão, A | 1 |
| Machado-Neto, JA | 1 |
| Butler, M | 1 |
| van Ingen Schenau, DS | 1 |
| Yu, J | 1 |
| Jenni, S | 1 |
| Dobay, MP | 1 |
| Hagelaar, R | 1 |
| Vervoort, BMT | 1 |
| Tee, TM | 1 |
| Hoff, FW | 1 |
| Meijerink, JP | 1 |
| Kornblau, SM | 1 |
| Bornhauser, B | 1 |
| Bourquin, JP | 1 |
| Kuiper, RP | 1 |
| van der Meer, LT | 1 |
| van Leeuwen, FN | 1 |
| Hu, YY | 1 |
| Tao, SD | 1 |
| Ma, JJ | 1 |
| Zhou, LT | 1 |
| Chen, Y | 1 |
| Yu, L | 1 |
| Li, Z | 1 |
| Wu, J | 1 |
| Sheng, L | 1 |
| Müschen, M | 1 |
| Xia, T | 1 |
| Wang, J | 1 |
| Wang, Y | 2 |
| Cai, J | 1 |
| Wang, M | 1 |
| Chen, Q | 1 |
| Song, J | 1 |
| Yu, Z | 1 |
| Huang, W | 1 |
| Fang, J | 1 |
| Barnes, MJ | 1 |
| Taylor, GA | 1 |
| Newell, DR | 1 |
| Gilbertsen, RB | 1 |
| Dong, MK | 1 |
| Kossarek, LM | 1 |
| Sircar, JC | 1 |
| Kostlan, CR | 1 |
| Conroy, MC | 1 |
| O'Brien, S | 1 |
| Benvenuto, JA | 1 |
| Estey, E | 1 |
| Beran, M | 1 |
| Felder, TB | 1 |
| Keating, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma[NCT02884453] | Phase 2 | 17 participants (Anticipated) | Interventional | 2016-07-19 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for adenine and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia.
Topics: Adenine; DNA-Binding Proteins; Humans; Molecular Targeted Therapy; Piperidines; Pre-B Cell Receptors | 2015 |
2 trials available for adenine and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amino Acids; Animals; Antineoplastic Agents; Apoptosis | 2021 |
Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
Topics: Acute Disease; Adenine; Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Drug Evalu | 1991 |
7 other studies available for adenine and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
The Bruton's tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicity.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Bispecific; Antineoplastic Agents, Immunol | 2020 |
AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis.
Topics: Adenine; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Cell Su | 2021 |
[SDF-1α/CXCR4 Mediated Drug Resistance Can be Reversed by Ibrutinib in Acute Lymphoblastic Leukemia].
Topics: Adenine; Chemokine CXCL12; Drug Resistance, Neoplasm; Humans; Piperidines; Precursor Cell Lymphoblas | 2017 |
Ibrutinib improves the development of acute lymphoblastic leukemia by activating endoplasmic reticulum stress-induced cell death.
Topics: Activating Transcription Factor 4; Adenine; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Survival; E | 2018 |
Inhibition of autophagy potentiates anticancer property of 20(S)-ginsenoside Rh2 by promoting mitochondria-dependent apoptosis in human acute lymphoblastic leukaemia cells.
Topics: Adenine; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Autophagy-Related Protein 5; Cell | 2016 |
Development of a whole cell assay to measure methotrexate-induced inhibition of thymidylate synthase and de novo purine synthesis in leukaemia cells.
Topics: Adenine; Antimetabolites, Antineoplastic; Child; Guanine; Humans; Inosine; Leukemia; Methotrexate; P | 2000 |
Selective in vitro inhibition of human MOLT-4 T lymphoblasts by the novel purine nucleoside phosphorylase inhibitor, CI-972.
Topics: Adenine; Cell Division; Deoxycytidine; Deoxyguanine Nucleotides; DNA Replication; Guanosine Triphosp | 1991 |